English EN Spanish ES French FR Chinese (Simplified) ZH-CN

Transplant

Transplant

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

26 Clinical Trials
Transplant NA Accepting Patients
nct/study# NA / PRO00006278

Analysis of stem cell products immunological parameters and recipient outcome in autologous and allogeneic peripheral blood stem cell transplantation

Learn More
Transplant NA Accepting Patients
nct/study# NA / CD34-REAGENT-SYSTEM-GVHD

This protocol is for the use of CliniMACS CD34 Reagent System in a single patient with relapsed AML. Patient received salvage chemo and planned stem cell boost for cytopenias. Since donor is a haplo, plan is to give CD34 selected cells with some t cell add back.

Learn More
Transplant NA Accepting Patients
nct/study# NA / PRO00001762

Analysis of Immune Repertoire in Patients undergoing Extracorporeal Photopheresis for the Treatment of Chronic GVHD

Learn More
Transplant NA Accepting Patients
nct/study# NA / PRO00005979

Retrospective Review of Viral Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation

Learn More
Transplant NA Accepting Patients
nct/study# NA / PRO2016-0399

Long-term cryopreservation of autologous hematopoietic stem cells

Learn More
Transplant NA Accepting Patients
nct/study# NCT03119363 / 11-01032-DR-RINI

Treating Cancer-Related Fatigue through Systematic Light Exposure (Light for Fatigue Study)

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.